Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas.

Lower urinary tract carcinomas in dogs are rare conditions with a poor prognosis. This prospective clinical study evaluated the safety, feasibility, and therapeutic efficacy of transarterial chemoembolization (TACE) using quick-soluble gelatin microparticles (QS-GMP) in 29 client-owned dogs with lower urinary tract carcinomas. Tumors primarily involved the bladder and urethra. Following selective catheterization of tumor-feeding vessels, intra-arterial carboplatin was administered prior to QS-GMP embolization. All patients underwent follow-up computed tomography (CT) scanning 4 weeks post-TACE. Tumor volume decreased in all cases, with a median reduction of 76.41% (95% confidence interval: 65.06-78.41%, p < 0.001). Partial remission was observed in 96.5% of patients; one case showed stable disease. Clinical signs, including pollakiuria, hematuria and stranguria, improved. No major complications occurred during the procedure or within two weeks after the procedure, and minor adverse effects were self-limiting. Repeat TACE was performed in 28/29 patients. The median survival time was 569 days for all patients and 534 days when non-tumor-related deaths were excluded. These findings suggest that TACE with QS-GMP may be an option for dogs with unresectable lower urinary tract carcinomas, with potential for repeated interventions and prolonged survival.